With the federal government's negotiation of prescription prices with drug companies about to get underway, briefs filed in suits seeking to overturn the program are providing a preview of the coming legal battle.
A plan to negotiate prices of prescription drugs covered under Medicare is facing multiple lawsuits from drugmakers, including at least four cases in New Jersey.
Bristol-Myers Squibb Co., Janssen Pharmaceuticals, Novartis Pharmaceuticals Corp. and Novo Nordisk have challenged the drug negotiation program in suits naming Health and Human Services Secretary Xavier Becerra.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Charles Toutant
Charles Toutant is a litigation writer for the New Jersey Law Journal.
